Cancer BiologybioRxiv
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
N. Fatima, Y. Shen, K. Crassini…·G. Best
This study shows TR-57 is effective as a single agent and in combination with venetoclax against CLL cells in vitro, regardless of TP53 aberrations.
DOI 10.1080/10428194.2023.2300055